Definium Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Definium Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($183.79M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($108.68M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($95.73M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($56.80M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($93.04M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($33.94M) | Mar 28, 2022 |
| FY2021 | Dec 31, 2019 | ($10.70M) | Mar 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($166.31M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($103.92M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($93.87M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($66.33M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($93.85M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($33.03M) | Mar 28, 2022 |
| FY2021 | Dec 31, 2019 | ($10.73M) | Mar 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.67M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $65.30M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $52.12M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $36.17M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $34.79M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $18.63M | Mar 28, 2022 |
| FY2021 | Dec 31, 2019 | $7.55M | Mar 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($131.56M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($79.13M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($64.37M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($50.14M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($45.82M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($23.60M) | Mar 28, 2022 |
| FY2021 | Dec 31, 2019 | ($3.20M) | Mar 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $440.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $302.15M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $124.54M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $169.99M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $164.00M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $81.52M | Mar 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.77M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $60.70M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $46.41M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $19.08M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $12.34M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $5.65M | Mar 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $332.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $241.45M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $78.13M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $150.92M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $151.66M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $75.87M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $4.78M | Mar 28, 2022 |
| FY2021 | May 29, 2019 | $0 | Mar 28, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.92M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.92M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $19.92M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $19.92M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $19.92M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($582.67M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($398.88M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($290.20M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($194.47M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($137.67M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($44.64M) | Mar 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $257.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $273.74M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $99.70M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $142.14M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $133.54M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $80.09M | Mar 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 98.78M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 75.10M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 41.10M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 37.98M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 28.13M | Mar 9, 2023 |